1887
Letter Open Access
Like 0
Preview this article:

There is no abstract available.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.4.2300034
2023-01-26
2024-02-27
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.4.2300034
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/4/eurosurv-28-4-4.html?itemId=/content/10.2807/1560-7917.ES.2023.28.4.2300034&mimeType=html&fmt=ahah

References

  1. van Ewijk CE, Kooijman MN, Fanoy E, Raven SF, Middeldorp M, Shah A, et al. COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021. Euro Surveill. 2022;27(45):2200217.  https://doi.org/10.2807/1560-7917.ES.2022.27.45.2200217  PMID: 36367011 
  2. World Health Organization (WHO). Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination: interim guidance, 1 October 2022: second addendum to Evaluation of COVID-19 vaccine effectiveness: interim guidance. Geneva: WHO; 2022. Available from: https://apps.who.int/iris/handle/10665/363344
  3. Government of the Netherlands. Netherlands to reopen further with coronavirus entry passes. Amsterdam: Government of the Netherlands; 2021. Available from: https://www.government.nl/latest/news/2021/09/14/netherlands-to-reopen-further-with-coronavirus-entry-passes
  4. Fisher KA, Tenforde MW, Feldstein LR, Lindsell CJ, Shapiro NI, Files DC, et al. Community and close contact exposures associated with COVID-19 among symptomatic adults ≥18 years in 11 outpatient health care facilities – United States, July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(36):1258-64.  https://doi.org/10.15585/mmwr.mm6936a5  PMID: 32915165 
  5. Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, et al. Behavioral factors associated with SARS-CoV-2 infection in Japan. Influenza Other Respir Viruses. 2022;16(5):952-61.  https://doi.org/10.1111/irv.12992  PMID: 35470969 
  6. Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. COVID-19 vaccine effectiveness by product and timing in New York State. medRxiv.  https://doi.org/10.1101/2021.10.08.21264595 
  7. Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, et al. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: a multi-center prospective case-control study (FASCINATE study). Clin Infect Dis. 2022;ciac635.  https://doi.org/10.1093/cid/ciac635  PMID: 35918782 
  8. Sullivan SG, Cowling BJ. "Crude vaccine effectiveness" is a misleading term in test-negative studies of influenza vaccine effectiveness. Epidemiology. 2015;26(5):e60.  https://doi.org/10.1097/EDE.0000000000000343  PMID: 26133018 
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error